Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.
about
Present Advances and Future Perspectives of Molecular Targeted Therapy for OsteosarcomaUnderstanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease ProgressionImmunotherapy for Bone and Soft Tissue SarcomasThe evolution of systemic therapy in sarcoma.Characterization of STAT3 activation and expression in canine and human osteosarcoma.Spontaneously occurring tumors of companion animals as models for human cancer.Historical overview of biologic response modifiers.Review of mifamurtide in the treatment of patients with osteosarcoma.The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.Toward a drug development path that targets metastatic progression in osteosarcoma.Prognostic factors in canine appendicular osteosarcoma - a meta-analysis.Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.Different patterns of macrophage infiltration into allogeneic-murine and xenogeneic-human neoplasms growing in nude miceStrategies and developments of immunotherapies in osteosarcomaLiposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.The Current and Future Therapies for Human Osteosarcoma.L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.Metastatic osteosarcoma: a review of current issues in systemic treatment.Current concepts on the surgical and medical management of osteosarcoma.Stem cell growth factor receptor in canine vs. feline osteosarcomas.Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.Mifamurtide for the treatment of nonmetastatic osteosarcomaOf dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma.Recent progress in canine tumor vaccination: potential applications for human tumor vaccines.Management of gastrointestinal stromal tumors.New drugs in sarcomas.Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.The immunotherapy of canine osteosarcoma: a historical and systematic review.Drugs in early clinical development for the treatment of osteosarcoma.Prevention of experimental endotoxin shock by a monocyte activator.Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells.Quantitative estimation of the thermal dose-modifying factor for cis-diamminedichloroplatinum (CDDP) in tumour-bearing dogs.Manipulation of Innate Immunity for Cancer Therapy in Dogs.A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats.Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies.
P2860
Q26750631-A77BC4BA-50A6-43A3-B501-6863C071E473Q26829949-3F4A7CE3-9B19-4A17-B1EE-2876B52AF6C3Q28088363-F948E9AB-0A47-4C75-936F-0432D0D4451EQ33274710-675DA70D-901B-4183-B830-531E5BA7B744Q33417870-D8C80D55-7197-4ED4-A49C-5FBB5F35F06FQ33927360-F7975798-B094-4A40-AF2E-9C8468FC3DDEQ33931138-63755C97-173B-4EE5-A459-7185F4C6A308Q33947618-25105C97-8364-47CC-8D61-CC37D9009D12Q34044072-B77AF0D4-DD59-4EDB-8838-BFDB647A1D72Q34052760-75EF89FA-9232-47A8-A284-02955B2563B6Q34269549-9A1BB430-1226-4400-AF34-9F129FD64AB7Q34588395-E1DE65B3-BFEF-4B0E-91FC-EB94C51A3638Q34996698-FC6CADB4-B745-4D3D-9203-608AA38FDFC2Q35832058-C4683CC0-1E7A-46A1-AE79-F8EE9E7B5B85Q36503128-1EA41F42-891F-4F62-91F9-832FF1FF96DEQ36512499-3F774EEA-1AE2-4680-A670-8B1597E76C78Q36514299-DA6BF240-F1EB-4CBB-8FE7-DB2E6FF6399FQ36853886-F22971D2-FC30-434D-9DFC-22E69FA54E97Q37180881-45CFD288-4E8B-488E-9118-E259859C5173Q37242673-30D43448-A388-4CF6-A94E-951508A9870CQ37288229-3A233134-6F6F-4CF2-95F0-90F5D38E325EQ37439345-439F715F-4E28-4CF7-8749-D64F311050B7Q37827876-60B5841F-E500-4237-A564-B74C1E24A3E9Q37944599-8E440968-8172-4CF5-8576-F6A422CBA441Q38068234-21CB5F07-DC51-4465-8CDE-D1A776AB9E63Q38081983-D1BA2A31-455E-465E-8D60-28F43BCCB8D8Q38165238-C95FC9A9-F61F-43C7-BF24-B5F9CDAED56DQ38220804-7D912239-B70C-456B-B156-11B7B12F304DQ38451770-B6D5A93D-E151-46BF-90B7-8029A9AFE84EQ38955517-9C0F7E59-4238-411D-892B-D756C412EDE4Q39780812-2A72AAC2-83F9-410D-8284-4F43B379F39EQ40499109-CE6EE9A9-6D9F-41F5-AF0E-4A935813E44BQ42253060-BDFBC48C-4275-4FCC-B3ED-FD96DE974550Q44856448-B098D13B-0902-4593-852C-DE0465D23F54Q47137850-ED1F35AE-D8B1-42F9-812F-23548361D6DEQ47967532-148851C4-4326-4F1A-9B95-89E827830DC1Q48160138-06AEA428-21FE-4C51-8A9F-85A1A2E69AE7Q55081994-5AC820EF-C713-4D3D-ADDE-62BCB350B88B
P2860
Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.
description
1989 nî lūn-bûn
@nan
1989 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Therapy for osteosarcoma in do ...... capsulated muramyl tripeptide.
@ast
Therapy for osteosarcoma in do ...... capsulated muramyl tripeptide.
@en
Therapy for osteosarcoma in do ...... capsulated muramyl tripeptide.
@nl
type
label
Therapy for osteosarcoma in do ...... capsulated muramyl tripeptide.
@ast
Therapy for osteosarcoma in do ...... capsulated muramyl tripeptide.
@en
Therapy for osteosarcoma in do ...... capsulated muramyl tripeptide.
@nl
prefLabel
Therapy for osteosarcoma in do ...... capsulated muramyl tripeptide.
@ast
Therapy for osteosarcoma in do ...... capsulated muramyl tripeptide.
@en
Therapy for osteosarcoma in do ...... capsulated muramyl tripeptide.
@nl
P2093
P356
P1476
Therapy for osteosarcoma in do ...... capsulated muramyl tripeptide.
@en
P2093
E G MacEwen
I D Kurzman
P A Manley
P E Howard
R C Rosenthal
P304
P356
10.1093/JNCI/81.12.935
P407
P577
1989-06-01T00:00:00Z